Research programme: Retinoid orphan receptor gamma T inhibitors - Lead Pharma/Sanofi

Drug Profile

Research programme: Retinoid orphan receptor gamma T inhibitors - Lead Pharma/Sanofi

Alternative Names: RORyT inhibitors

Latest Information Update: 11 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lead Pharma
  • Developer Lead Pharma; Sanofi
  • Class Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders

Most Recent Events

  • 27 Feb 2017 Early research in Autoimmune disorders in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top